Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lidorestat SCHEMBL29387869 | 0.87 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL419032 | 0.87 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Lidorestat SCHEMBL6103908 | 0.86 | AKR1A1 (0.98) | AKR1A1AKR1B1 | |
| SCHEMBL4164332 | 0.83 | AKR1A1 (0.58) | AKR1A1AKR1B1 | |
| SCHEMBL419953 | 0.82 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL8655001 | 0.80 | AKR1A1 (0.52) | AKR1A1AKR1B1 | |
| SCHEMBL443358 | 0.79 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL443930 | 0.78 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL2099099 | 0.78 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL445068 | 0.78 | AKR1A1 (1.00) | AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314257-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-8198314-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8163931-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-04-24 | — | — | US | disclosed |
| US-8163936-B2 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2012-04-24 | — | — | US | disclosed |
| US-7582672-B2 | Compounds for the treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| EP-1682121-B1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | OXAGEN LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| EP-2060258-A1 | Use of CRTH2 antagonist compounds in therapy | Oxagen Limited (GB) | 2009-05-20 | — | — | EP | disclosed |
| US-20090023788-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090018138-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018139-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018338-A1 | Treatment of CRTH2-Mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1682121-A1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | Oxagen Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044260-A1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | OXAGEN LIMITED (GB) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023788-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | AKR1A1 990/4885AKR1B1 585/4885 |
| US-20090018138-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | AKR1A1 990/4885AKR1B1 585/4885 |
| US-20090018338-A1 | Treatment of CRTH2-Mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | AKR1A1 990/4885AKR1B1 585/4885 |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | AKR1A1 990/4885AKR1B1 585/4885 |
| US-20090018139-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | AKR1A1 990/4885AKR1B1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.